MedWatch

Zealand Pharma sends obesity candidate to clinic

Zealand Pharma has started a phase I study of the drug candidate ZP8396, which the company hopes will become an effective treatment for obesity. The trial is expected to be finished in September 2022.

Emmanuel Dulac - CEO at Zealand Pharma | Photo: Stine Bidstrup ERH

Danish pharmaceutical company Zealand Pharma wants a slice of the lucrative market for obesity treatments.

The listed company has announced a phase I trial of a drug candidate, currently called ZP8396, which must now prove its worth as a treatment for the condition.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs